Mersana Therapeutics, Inc. Presents Data Demonstrating XMT-1001 Substantially Accumulates in Tumor and Results in Significantly Prolonged Drug Exposure
4/20/2010 11:39:06 AM
CAMBRIDGE, Mass., April 20 /PRNewswire/ -- Mersana Therapeutics, a platform-based cancer therapeutics company, announced today positive preclinical pharmacokinetic data for its lead development candidate, XMT-1001, which is currently in a Phase 1 clinical trial in patients with advanced solid tumors. The results were presented in a poster session at the AACR 101st Annual Meeting 2010 in Washington, DC, held April 17-21, 2010. XMT-1001 is a conjugate of the anti-cancer molecule camptothecin (CPT) that employs Mersana's Fleximer® platform. Data from the study demonstrated that XMT-1001 substantially accumulates in tumors and tissue and provides significantly prolonged exposure to the conjugate drug and its release products, including highly potent CPT, providing potential efficacy and safety advantages.